How is Ceftriaxone sulbactum combination better than ceftriaxone tazobactum?
ceftriaxone is ase third genration antibiotic and having good
coverage againast gram positive and grame neative ,while sulbuctem
increase its activity against betalactamase producing bcteria.
Asked in Medication and Alcohol Interactions
Can you take alcohol while taking Ceftriaxone Sodium?
Can Azithromycin be taken 12 hours after ceftriaxone injection for gonorrhea?
Asked in Typhoid Fever
What is the route of administration of ceftriaxone injection in typhoid treatment?
Asked in Health, Medication and Drugs
Is the drug ceftriaxone the same as unasyn?
Asked in Health, Essays, The Difference Between
How do you calculate Assay of Ceftriaxone sodium BP on anhydrous basis?
Asked in Medication and Drugs
Is ringer lactate is compatible with ceftriaxone inj?
Information for Healthcare Professionals: Ceftriaxone (marketed as Rocephin and generics)Last updated: 4/21/2009 This Alert highlights important revisions to the Warnings, Dosage and Administration, Contraindications, and Clinical Pharmacology sections of the full prescribing information for ceftriaxone (Rocephin and its generics). This information updates a previous Alert and addresses the interaction of ceftriaxone with calcium-containing products, based on previously reported fatal cases in neonates. At the request of FDA, the manufacturer of ceftriaxone (Roche) conducted two in vitro studies to assess the potential for precipitation of ceftriaxone-calcium when ceftriaxone and calcium-containing products are mixed in vials and in infusion lines. These two in vitro studies were conducted in neonatal and adult plasma to assess the potential for precipitation of ceftriaxone-calcium using varying ceftriaxone and calcium concentrations, including concentrations in excess of those achieved in vivo.* Based on the results from these studies, FDA has the following updated recommendations: Concomitant use of ceftriaxone and intravenous calcium-containing products is contraindicated in neonates (<28 days of age). Ceftriaxone should not be used in neonates (<28 days of age) if they are receiving (or are expected to receive) calcium-containing intravenous products. In patients >28 days of age, ceftriaxone and calcium-containing products may be administered sequentially, provided the infusion lines are thoroughly flushed between infusions with a compatible fluid. Ceftriaxone must not be administered simultaneously with intravenous calcium-containing solutions via a Y-site in any age group. FDA now recommends that ceftriaxone and calcium-containing products may be used concomitantly in patients >28 days of age, using the precautionary steps above because the risk of precipitation is low in this population. FDA had previously recommended, but no longer recommends, that in all age groups ceftriaxone and calcium-containing products should not be administered within 48 hours of one another